3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
13
Breast
4
Tumor-Agnostic
1
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Conditions
Recurrence
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Carboplatin
510
Cisplatin
410
Pemetrexed
400
Radiotherapy
285
Docetaxel
244
Paclitaxel
227
pembrolizumab
226
Gemcitabine
198
Drug Therapy
191
Bevacizumab
190
Erlotinib Hydrochloride
189
Radiosurgery
177
Nivolumab
168
Etoposide
155
durvalumab
154
osimertinib
126
atezolizumab
109
Gefitinib
96
Blood Specimen Collection
93
Magnetic Resonance Spectroscopy
91
Vinorelbine
90
anlotinib
88
Surgical Procedures, Operative
85
Ipilimumab
62
Immunotherapy
62
Surveys and Questionnaires
60
sintilimab
59
Specimen Handling
59
tislelizumab
58
Irinotecan
57
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
XRP6258
×
Thoracic
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled